Search results

1

L-MTO-PE - a potential drug for cancer therapy

100%

Dzierzbicka K., Gozdowska M., Kolodziejczyk A. M.

Postępy Higieny i Medycyny Doświadczalnej

|

1997

|

vol. 51

|

issue 2

227-236

EN

Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a syntetic lipophilic analogue of muramyl dipeptide, stimulates monocytes/macrophages to kill a variety of tumor cells in vitro and in vivo. Encapsulation of MTP-PE into multilamellar liposomes (L-MTP-PE) was specifically designed for in vivo targeting to macrophages by i.v. infusion and is the only form of the drug currently available for clinical trials (CGP 19835A Lipid). L-MTP-PE is presently undergoing clinical trials in patients with recurrent osteosarcoma and melanoma. L-MTP-PE combined with other anticancer agents may thus improve long-term cure rates of patients with this diseases.

2

Fatty acids as a potential adjuvant in cancer therapy

63%

Przybyszewski W. M., Widel M.

Postępy Higieny i Medycyny Doświadczalnej

|

2002

|

vol. 56

|

issue 5

589-602

EN

This review presents pro- and anticancer effects of fatty acids in vitro and in vivo. The epidemiological and experimental data indicate that short-chain saturated and long-chain unsaturated omega-3 fatty acids exert protective effects against some cancers. In the contrary, omega-6 fatty acids are rather procancerous and can increase tumour proliferation. The possible mechanisms are still not fully understood and are very variable including: suppression of neoplastic transformation, direct cytotoxicity, apoptosis induction, antiangiogenicity etc. Experimental data indicate that fatty acid composition of cancer cells in cultures or in animals can be modified to make the cells more susceptible to lipid peroxidation, increasing the cell damage due to oxidant stress and make the cells more sensitive to chemotherapy. It is reasonable to suppose that fatty acids supplementation can make an enrichment of traditional tools for modern anticancer strategies.

3

Antisense oligonucleotides: from the bench to the patients

51%

Skorski T., Nieborowska-Skorska M., Szczylik C., Calabretta B.

Biotechnologia

|

1996

|

issue 4

108-115

EN

We describe here tha current state of progress toward gene-directed antisense-based cancer therapy targeting BCR/ABL, oncogene, primarily from the viewpoint of initial proof-of-concepts studies in animal models of human leukemias and phase I clinical investigations.

4

The perspectives the antisense strategy applicatgion in the clinical medicine

51%

Ratajczak M. Z., Skorski T., Bialek A.

Biotechnologia

|

1995

|

issue 1

35-43

EN

In this review paper the different aspects and perspectives of antisense strategy applications in clinical medicine are discussed.

5

Modulation of apoptosis signaling for cancer therapy

51%

Fulda S., Debatin K.-M.

Archivum Immunologiae et Therapiae Experimentalis

|

2006

|

vol. 54

|

issue 3

173-175

EN

Apoptosis, the cell's intrinsic death program, plays a central role in regulating tissue homeostasis. Also, most cytotoxic therapies used for cancer treatment, such as chemotherapy, g-irradiation, suicide genes, or immunotherapy, predominantly act by triggering apoptosis in target cells. Thus, understanding the molecular events that regulate apoptosis and how tumor cells evade apoptotic deletion have provided a paradigm to link cancer genetics and response to cancer therapy. Therefore, insights into the mechanisms regulating drug-induced apoptosis provide rational targets for novel therapeutic interventions.

6

RNA interference-based therapeutics in anticancer therapy

51%

Kaminska B., Kulesza D., Wisniewski P.

Biotechnologia

|

2010

|

issue 3

94-114

EN

RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing and its discovery led to wide applications. Short interfering RNA (siRNA), which induces RNAi, has been experimentally introduced as a cancer therapy and is expected to be developed as a nucleic acid-based medicine. Potential success of siRNA cancer therapies depends on selection of appropriate gene targets and candidate targets include genes associated with cell proliferation, metastasis, angiogenesis, and drug resistance. In vivo systemic delivery of siRNA-based therapeutics to tumour tissues is challenging and the major limitations of siRNA therapeutic use are its degradation by serum nucleases, poor cellular uptake and rapid renal clearance following systemic administration. Several siRNA-based therapeutics are already in clinical trials. Further development of anti-cancer therapeutic siRNAs depends on development of nanocarriers, nuclease-resistant chemically modified siRNAs and variety of synthetic or natural lipids and polymers to systemically deliver siRNA. Here, we review potential approaches for delivery of RNAi based therapeutic in cancer therapy, results of current studies and clinical trials which demonstrate that the use of targeted siRNA offers promising strategies for cancer therapies.

7

Cancer stem cells as targets for cancer therapy: Selected cancers as examples

38%

Hombach-Klonisch S., Paranjothy T., Wiechec E., Pocar P., Mustafa T., Seifert A., Zahl C., Gerlach K. L., Biermann K., Steger K., Hoang-Vu C., Schulze-Osthoff K., Los M.

Archivum Immunologiae et Therapiae Experimentalis

|

2008

|

vol. 56

|

issue 3

165-180

EN

It is becoming increasingly evident that cancer constitutes a group of diseases involving altered stem-cell maturation/differentiation and the disturbance of regenerative processes. The observed malignant transformation is merely a symptom of normal differentiation processes gone astray rather than the primary event. This review focuses on the role of cancer stem cells (CSCs) in three common but also relatively under-investigated cancers: head and neck, ovarian, and testicular cancer. For didactic purpose, the physiology of stem cells is first introduced using hematopoietic and mesenchymal stem cells as examples. This is followed by a discussion of the (possible) role of CSCs in head and neck, ovarian, and testicular cancer. Aside from basic information about the pathophysiology of these cancers, current research results focused on the discovery of molecular markers specific to these cancers are also discussed. The last part of the review is largely dedicated to signaling pathways active within various normal and CSC types (e.g. Nanog, Nestin, Notch1, Notch2, Oct3 and 4, Wnt). Different elements of these pathways are also discussed in the context of therapeutic opportunities for the development of targeted therapies aimed at CSCs. Finally, alternative targeted anticancer therapies arising from recently identified molecules with cancer-(semi-)selective capabilities (e.g. apoptin, Brevinin-2R) are considered.

Refine search results

L-MTO-PE - a potential drug for cancer therapy

Fatty acids as a potential adjuvant in cancer therapy

Antisense oligonucleotides: from the bench to the patients

The perspectives the antisense strategy applicatgion in the clinical medicine

Modulation of apoptosis signaling for cancer therapy

RNA interference-based therapeutics in anticancer therapy

Cancer stem cells as targets for cancer therapy: Selected cancers as examples